HOME >> MEDICINE >> NEWS
Disoriented T cells cause liver disease

T cells activated in the gut during inflammatory bowel disease can be re-routed to the liver and cause chronic liver disease, according to Eksteen and colleagues in the December 1 issue of The Journal of Experimental Medicine.

A chronic liver disease known as primary sclerosing cholangitis (PSC) has been linked to inflammatory bowel disease (IBD) in the past. But the connection between the two disorders has been unclear, especially as the liver condition often develops years after IBD has resolved or the colon has been surgically removed. Eksteen and colleagues now show that T cells that were activated in the gut probably during IBD - are found in the livers of patients with PSC, but not in those of patients with other inflammatory liver diseases.

The authors explain this detour by showing that an attractant protein that normally directs T cells into the gut is aberrantly produced in the liver during PSC. T cells expressing the receptor for the protein are thus re-routed to the liver, although the authors do not know what triggers liver cells to make the attractant in the first place. T cells can survive as memory cells for many years after they are activated, and the authors believe this may explain how the liver disease can crop up years after IBD has resolved.


'"/>

Contact: Nikki Henry
henryn@rockefeller.edu
212-327-8366
Journal of Experimental Medicine
29-Nov-2004


Page: 1

Related medicine news :

1. Suppressing the cells that trigger cat allergy
2. Indiana University researchers closer to helping hearing-impaired using stem cells
3. Some brain cells change channels to fine-tune the message
4. Hopkins begins human trials with donor adult stem cells to repair muscle damaged from heart attack
5. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
6. Study suggests smoking while pregnant may increase chromosomal abnormalities in fetal cells
7. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
8. Smart immune cells kill more cancer
9. CK2 protein sustains colon cancer cells by sabotaging ability to commit suicide
10. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
11. PCBs, fungicide open brain cells to Parkinsons assault

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® ... ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein costs. “Soy ... cost savings as well as more stable pricing over time. Now it’s even ...
(Date:4/25/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically ... aging, and minimize the appearance of pores – all with minimal downtime and ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and funding ... randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced ...
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
Cached News: